▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2138 by analyst upside · 2026-11-12
SOPH
SOPHiA GENETICS SA
Healthcare · Market Cap $639M · P/E 0x
ANALYST PRICE TARGET
+30.6%
implied upside to consensus target
Current Price $7.46
Consensus Target $9.75
Bull Target $14.0
Bear Target $7.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $3.83
52-Week High $8.98
YTD Return +59.9%
FUNDAMENTALS
Market Cap $639M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.03
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $91M
Profit Margin -89.2%
52-WEEK RANGE
52-Week Low $3.83
52-Week High $8.98
Current Price $7.46
Bear Target $7.0
Bull Target $14.0
● Now $7.46 ● Target $9.75
TRADING DATA
Avg Volume 638K
YTD Return +59.9%
Analyst Count 4
Consensus Buy
Upside to Target +30.6%
Last Updated 2026-11-12

ANALYST SUMMARY

SOPHiA GENETICS SA (SOPH) is currently trading at $7.46 with a Wall Street consensus price target of $9.75, implying potential upside of 30.6% over the next 12 months. 4 analysts currently cover SOPH, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $7.0.

SOPH operates in the Healthcare sector with a market capitalisation of $639M. The stock is up 59.9% year-to-date and is currently trading near the upper end of its 52-week range of $3.83 – $8.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ABUS +37.9%
Arbutus Biopharma Corporation
$595M · P/E 3.4x · Buy
IRWD +25.3%
Ironwood Pharmaceuticals, Inc.
$806M · P/E 5.4x · Buy
BVS +51.0%
Bioventus Inc.
$753M · P/E 13.6x · Buy
INMD +17.7%
InMode Ltd.
$790M · P/E 11.0x · Hold
RIGL +33.1%
Rigel Pharmaceuticals, Inc.
$838M · P/E 2.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for SOPH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-10-12 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-05 31% win rate (48 calls)
BTIG - Reiterated
Buy → Buy 2026-08-05 38% win rate (8 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-07-20 31% win rate (48 calls)
BTIG reit
Buy → Buy 2026-06-15 38% win rate (8 calls)
BTIG reit
Buy → Buy 2026-05-06 38% win rate (8 calls)
BTIG - Reiterated
Buy → Buy 2026-04-15 38% win rate (8 calls)
Guggenheim - Reiterated
Buy → Buy 2026-01-26 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
12/30
Consensus clarity
11/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →